Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  NASDAQ OMX STOCKHOLM  >  RaySearch Laboratories AB (publ)    RAY B   SE0000135485


SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

RaySearch Laboratories : will present further advances in machine learning and support for brachytherapy at ASTRO 2020

10/23/2020 | 09:01am EST

RaySearch Laboratories AB (publ) will demo its latest advances in oncology software at the American Society for Radiation Oncology (ASTRO) 2020 Annual Meeting. Visitors will be offered the opportunity to book personal online demos of treatment planning system RayStation®* and oncology information system RayCare®*.


RaySearch will present recent and upcoming enhancements, as well as new functionality, in RayStation and RayCare. Among the highlights in RayStation are support for brachytherapy planning and robust proton planning using machine learning. In RayCare, additional automation capabilities will be on show - such as support for scripting and enhanced workflow management tools.

Brachytherapy planning in RayStation
The upcoming release of RayStation 10B is expected in December 2020* and will add support for brachytherapy planning. This is in line with the company's aim to support as many treatment delivery systems as possible. RayStation will feature automatic channel reconstruction in combination with powerful dwell time optimization to make the creation of high-quality brachy plans faster and more consistent.

Machine learning planning in RayStation
Machine learning capabilities were added to RayStation 8B and are being continuously improved. Their applications in RayStation increase efficiency and improve consistency, while facilitating model sharing between cancer clinics. ASTRO 2020 will see demos of machine-learning planning for photons and robust proton planning - as well as deep-learning organ segmentation.

Johan Löf, founder and CEO, RaySearch, says: "Machine learning is without doubt one of the most exciting developments within medical software right now. Harnessing the massive potential of machine learning will transform the industry and improve access to and the quality of cancer treatment."

RayCare further promotes efficiency and safety
Released in June 2020, RayCare 4A further promotes efficiency and safety by reducing routine manual tasks and handovers. Its unique workflow management capabilities are enhanced by the introduction of task management for clinical teams. Further functionalities in RayCare 4A include support for scripting as well as automated support for running RayStation scripts from tasks with forks - as well as several new patient chart features. RayCare 4B is expected in December 2020*.

Virtual demonstrations
Visitors to ASTRO 2020 will be offered the opportunity to book personal online demos of treatment planning system RayStation and oncology information system RayCare. 

Partnerships play a crucial role in the development of RayStation and on show at ASTRO 2020 will be the ways in which RaySearch is creating new levels of advanced efficiency in radiotherapy imaging and planning together with Accuray, Canon Medical and IBA:

Demos of RayStation and RayCare functionality for the TomoTherapy® delivery system from Accuray will be available. RayStation includes full support for the TomoTherapy and Radixact® Systems, including advanced features such as multi-criteria optimization, adaptive planning and Plan Explorer.

Canon Medical and RaySearch are collaborating on a highly flexible and efficient workflow for virtual simulation, which complements Canon Medical's CT, PET/CT, and MRI simulators. It can optionally be expanded with deformable registration.

IBA and RaySearch entered into a long-term strategic collaboration in 2016 to combine their respective technologies and future developments in proton therapy such as motion management, adaptive, ARC and FLASH therapy. In both RayStation and RayCare, as well as in the IBA delivery solutions, joint features, dedicated software interfaces and modified graphical user interface components facilitate close and seamless workflow integration with optimized performance. In July 2020, the first patients were treated with this common solution at Particle Center at University of Leuven in Belgium.

For further information, please contact:
Johan Löf, Founder and CEO, RaySearch Laboratories AB (publ)
Telephone: +46 (0)8-510 530 00

Peter Thysell, CFO, RaySearch Laboratories AB (publ) 
Telephone: +46 (0)70 661 05 59

About RaySearch
RaySearch is a medical technology company that develops innovative software solutions to improve cancer care. The company markets worldwide its treatment planning system RayStation and next-generation oncology information system RayCare. Over 2,600 clinics in more than 65 countries use RaySearch software to improve life and outcomes for patients. The company was founded in 2000 and the share has been listed on Nasdaq Stockholm since 2003.

About RayStation
RayStation is a flexible, innovative treatment planning system, chosen by many of the leading cancer centers worldwide. It combines unique features such as unmatched adaptive therapy capabilities, multi-criteria optimization, market-leading algorithms for IMRT and VMAT optimization with highly accurate dose engines for photon, electron, proton and carbon ion therapy. RayStation supports a wide range of treatment machines, providing one control center for all treatment planning needs and ensuring centers get greater value from existing equipment. RayStation also seamlessly integrates with RayCare, the next-generation oncology information system. By harmonizing the treatment planning, we enable better care for cancer patients worldwide. 

About RayCare
RayCare is designed to support the complex logistical challenges of modern oncology clinics. It represents the future of oncology information system technology, supporting the vision of one oncology workflow. Many cancer patients receive a combination of treatment types, and RayCare is designed to reflect that. It will efficiently coordinate activities in radiation therapy, chemotherapy and surgery and will offer advanced features for clinical resource optimization, workflow automation and adaptive radiation therapy. RayCare is being developed with tomorrow's requirements for advanced analytics and decision support in mind.

* Subject to regulatory clearance in some markets.

More information about RaySearch is available at www.raysearchlabs.com




(c) 2020 Cision. All rights reserved., source Press Releases - English

Stocks mentioned in the article
ChangeLast1st jan.
ACCURAY INCORPORATED 6.42% 4.31 Delayed Quote.43.62%
RAYSEARCH LABORATORIES AB (PUBL) 0.80% 75.2 Delayed Quote.-29.85%
11/27RAYSEARCH LABORATORIES : Introduction of RayIntelligence and the latest releases..
11/18RAYSEARCH LABORATORIES : Interim report january 1 - september 30, 2020
11/11RAYSEARCH LABORATORIES : Raystation support for boron neutron capture therapy no..
10/23RAYSEARCH LABORATORIES : will present further advances in machine learning and s..
09/16RAYSEARCH LABORATORIES : Cutting-edge cancer treatment comes to Belgium with the..
08/28RAYSEARCH LABORATORIES : RayStation in clinical use at both of Spain's proton ce..
08/26RAYSEARCH LABORATORIES : Interim report January 1 - June 30, 2020
07/15RAYSEARCH LABORATORIES PUBL : and TAE Life Sciences announce agreement on RaySta..
07/09RAYSEARCH LABORATORIES PUBL : Further clinical implementation of deep learning s..
06/30RAYSEARCH LABORATORIES PUBL : Bulletin from the Annual General Meeting 2020
More news
Sales 2020 764 M 90,3 M 90,3 M
Net income 2020 61,0 M 7,22 M 7,22 M
Net cash 2020 17,5 M 2,07 M 2,07 M
P/E ratio 2020 42,4x
Yield 2020 0,33%
Capitalization 2 578 M 305 M 305 M
EV / Sales 2020 3,35x
EV / Sales 2021 2,82x
Nbr of Employees 403
Free-Float 69,7%
Duration : Period :
RaySearch Laboratories AB (publ) Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends RAYSEARCH LABORATORIES AB (PUBL)
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus HOLD
Number of Analysts 2
Average target price 91,00 SEK
Last Close Price 75,20 SEK
Spread / Highest target 22,3%
Spread / Average Target 21,0%
Spread / Lowest Target 19,7%
EPS Revisions
Johan Löf President, Chief Executive Officer & Director
Lars Micael Wollung Chairman
Peter Thysell Chief Financial Officer
Kjell Eriksson Chief Research Officer
Carl Filip Bergendal Director
Sector and Competitors
1st jan.Capitalization (M$)
VEEVA SYSTEMS INC.94.72%41 311
OMNICELL, INC.27.74%4 416
SECTRA AB (PUBL)75.96%3 138
B-SOFT CO.,LTD.22.24%2 642